Zoetis (NYSE:ZTS) Reaches New 52-Week Low – Here’s Why

Zoetis Inc. (NYSE:ZTS) shares hit a new 52-week low during mid-day trading on Wednesday. The company traded as low as $69.52 and last traded at $69.7640, with a volume of 2517368 shares changing hands. The stock had previously closed at $70.30.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ZTS. Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a research report on Tuesday, August 25th. William Blair reiterated a “market perform” rating on shares of Zoetis in a research report on Thursday, August 6th. HSBC cut their price target on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research note on Monday, July 6th. JPMorgan Chase & Co. lowered their price objective on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Finally, Barclays dropped their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a report on Wednesday, July 1st. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Zoetis has an average rating of “Hold” and a consensus price target of $101.08.

Zoetis Stock Performance

The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The stock has a market cap of $28.83 billion, a PE ratio of 11.49, a price-to-earnings-growth ratio of 1.67 and a beta of 0.73. The business has a 50 day moving average price of $74.70 and a two-hundred day moving average price of $87.21.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same period in the previous year, the firm earned $1.76 earnings per share. The firm’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Zoetis

Hedge funds and other institutional investors have recently modified their holdings of the company. J. Stern & Co. LLP grew its stake in shares of Zoetis by 12,431.2% in the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after purchasing an additional 23,877,416 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after purchasing an additional 3,845,869 shares in the last quarter. State Street Corp increased its position in shares of Zoetis by 1.8% during the second quarter. State Street Corp now owns 19,667,723 shares of the company’s stock valued at $1,413,323,000 after buying an additional 343,322 shares during the period. Deutsche Bank AG increased its position in shares of Zoetis by 19.1% during the fourth quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock valued at $699,331,000 after buying an additional 891,921 shares during the period. Finally, Bank of America Corp DE raised its stake in Zoetis by 7.3% in the first quarter. Bank of America Corp DE now owns 4,831,652 shares of the company’s stock worth $571,150,000 after buying an additional 327,313 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.

The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.

Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health.